Table 8 Diagnostic performance of MDCT cholangiography
From: Validity of MDCT cholangiography in differentiating benign and malignant biliary obstruction
| Â | SN (%) (95%CI) | SP (%) (95%CI) | PPV (%) (95%CI) | NPV (%) (95%CI) | Acc (%) (95%CI) |
|---|---|---|---|---|---|
Intrahepatic | 100% | 100% | 100% | 100% | 100% |
(73.54–100) | (93.73–100) | (73.54–100) | (93.73–100) | (94.79–100) | |
Hilar | 100% | 100% | 100% | 100% | 100% |
(76.84–100) | (93.51–100) | (76.84–100) | (93.51–100) | (94.79–100) | |
Distal | 100% | 100% | 100% | 100% | 100% |
(91.78–100) | (86.77–100) | (91.78–100) | (86.77–100) | (94.79–100) | |
Malignant cause | 100% | 90.32% | 92.68% | 100% | 95.65% |
(90.75–100) | (74.25–97.96) | (80.08–98.46) | (87.66–100) | (87.82–99.09) | |
Calcular | 94.12% | 98.08% | 94.12% | 98.08% | 97.10% |
(71.31–99.85) | (89.74–99.95) | (71.31–99.85) | (89.74–99.95) | (89.92–99.65) | |
Benign stricture | 40% | 98.44% | 66.67% | 95.45% | 94.20% |
(5.27–85.34) | (91.60–99.96) | (9.43–99.16) | (87.29–99.05) | (85.82–98.40) | |
Malignant stricture | 94.44% | 93.94% | 94.44% | 93.94% | 94.20% |
(81.34–99.32) | (79.77–99.26) | (81.34–99.32) | (79.77–99.26) | (85.82–98.40) | |
Iatrogenic | 100% | 100% | 100% | 100% | 100% |
(39.76–100) | (94.48–100) | (39.76–100) | (94.48–100) | (94.79–100) | |
Inflammatory | 100% | 100% | 100% | 100% | 100% |
(29.24–100) | (94.56–100) | (29.24–100) | (94.56–100) | (94.79–100) | |
Portahepatis lesions | 100% | 98.48% | 75% | 100% | 98.55% |
(29.24–100) | (91.84–99.96) | (19.41–99.37) | (94.48–100) | (92.19–99.96) | |
Congenital | 100% | 100% | 100% | 100% | 100% |
(2.50–100) | (94.72–100) | (2.50–100) | (94.72–100) | (94.79–100) |